启迪药业：公司控制权拟发生变更

Core Viewpoint - The announcement indicates a significant change in the ownership structure of Qidi Pharmaceutical, with Hunan Sailuxian acquiring 24.47% of the company's shares, leading to a change in control and potential impacts on corporate governance [1] Summary by Relevant Sections Ownership Change - Qidi Pharmaceutical announced that on August 6, it received an execution ruling from the Beijing Financial Court, transferring 58.607 million shares (24.47% of total shares) from Qidi Kefu to Hunan Sailuxian [1] - Following this transfer, Qidi Kefu will no longer hold any shares in Qidi Pharmaceutical, reducing its and its concerted action party, Huaqing Investment's total shareholding to 4.5445 million shares (1.90% of total shares) [1] Impact on Corporate Governance - The acquisition of a controlling stake by Hunan Sailuxian is expected to have a significant impact on the company's ownership structure and governance [1]